Evidence map›Paper›PMID 37175265›Full record

ArticleMolecules (Basel, Switzerland)2023

Biological Evaluation of Triorganotin Derivatives as Potential Anticancer Agents.

Valeria Stefanizzi, Antonella Minutolo, Elena Valletta, Martina Carlini, Franca M Cordero, Anna Ranzenigo, Salvatore Pasquale Prete, Daniel Oscar Cicero, Erica Pitti, Greta Petrella and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Triorganotin compounds as emerging nuclear retinoid X receptor ligands and their implications in cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Valeria StefanizziDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-0516-5683
Antonella MinutoloDepartment of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-4784-4297
Elena VallettaDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.
Martina CarliniDepartment of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Franca M CorderoDepartment of Chemistry Ugo Schiff, University of Florence, 50019 Florence, Italy.ORCID 0000-0001-6005-5941
Anna RanzenigoDepartment of Chemistry Ugo Schiff, University of Florence, 50019 Florence, Italy.
Salvatore Pasquale PreteDepartment of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Daniel Oscar CiceroDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-5012-1714
Erica PittiDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.
Greta PetrellaDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-9449-9820
Claudia MatteucciDepartment of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-6058-1092
Francesca Marino-MerloDepartment of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0001-7898-583X
Antonio MastinoThe Institute of Translational Pharmacology, CNR, 00133 Rome, Italy.ORCID 0000-0002-0338-6450
Beatrice MacchiDepartment of Chemical Science and Technology, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-0878-1799
University of Rome Tor Vergata · ITUniversity of Florence · ITIstituto di Farmacologia Traslazionale · ITUniversity of Messina · IT

Funding

Italian Ministry of University and Research PRIN 2017M8R7N9_002
6 · The paper itself

Abstract

Metal-derived platinum complexes are widely used to treat solid tumors. However, systemic toxicity and tumor resistance to these drugs encourage further research into similarly effective compounds. Among others, organotin compounds have been shown to inhibit cell growth and induce cell death and autophagy. Nevertheless, the impact of the ligand structure and mechanisms involved in the toxicity of organotin compounds have not been clarified. In the present study, the biological activities of commercially available bis(tributyltin) oxide and tributyltin chloride, in comparison to those of specially synthesized tributyltin trifluoroacetate (TBT-OCOCF

Indexed as

Antineoplastic AgentsCoordination ComplexesOrganotin CompoundsTrialkyltin CompoundsCell Line, TumorCisplatinAntineoplastic Agentsbis(tri-n-butyltin)oxideCisplatinCoordination ComplexesOrganotin CompoundsTrialkyltin Compoundstributyltinanticancer agentscell deathcytotoxicitygrowth inhibitionorganotin derivativestintumor cells

Identifiers

PMID37175265
PMCPMC10180515
OpenAlexW4368404739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.